J. Goldman & CO LP Chimerix Inc Transaction History
J. Goldman & CO LP
- $3.27 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding CMRX
# of Institutions
81Shares Held
36.8MCall Options Held
72.2KPut Options Held
169K-
Ra Capital Management, L.P. Boston, MA8.8MShares$8.54 Million0.12% of portfolio
-
Monaco Asset Management Sam4.38MShares$4.25 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$4.22 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY2.22MShares$2.16 Million0.03% of portfolio
-
Acadian Asset Management LLC Boston, MA2.17MShares$2.11 Million0.01% of portfolio
About CHIMERIX INC
- Ticker CMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,622,896
- Market Cap $85M
- Description
- Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...